Latest & greatest articles for dabigatran

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dabigatran or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dabigatran and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dabigatran

61. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

62. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C CRD summary (...) All-cause deaths were equivalent for each treatment, but apixaban and dabigatran 110mg seemed to prevent more strokes, with least risk, for patients with non-valvular atrial fibrillation; dabigatran 150mg seemed better for patients at high risk of embolism. The review was generally poorly reported. The indirect comparisons and potential for confounding mean that the conclusions may not be reliable. Authors' objectives To compare the efficacy and safety of dabigatran, rivaroxaban, and apixaban

2012 DARE.

63. Dabigatran (Pradaxa?): risk of serious haemorrhage

Dabigatran (Pradaxa?): risk of serious haemorrhage Dabigatran (Pradaxa▼): risk of serious haemorrhage - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Dabigatran (Pradaxa▼): risk of serious haemorrhage Contraindications clarified and reminder to monitor renal function. Published 11 December 2014 From: Therapeutic area: , Contents Article date: July 2012 Dabigatran (Pradaxa▼) is a reversible inhibitor of free thrombin, fibrin-bound thrombin, and thrombin-induced platelet (...) aggregation. It is licensed for primary prevention of venous thromboembolic events in adults who have had elective total hip replacement surgery or total knee replacement surgery (at 220 mg/day), and for prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation and one or more cardiovascular risk factors (at 300 mg/day). Haemorrhage is a common adverse reaction with dabigatran. A review of world-wide data on the risk of bleeding with dabigatran, including results from

2012 MHRA Drug Safety Update

64. Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain

Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain Gonzalez-Juanatey JR, Alvarez-Sabin J, Lobos JM, Martinez-Rubio A, Reverter JC, Oyaguez I, Gonzalez-Rojas N, Becerra V Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of dabigatran compared with warfarin and other prescribing patterns for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in Spain. The authors concluded that dabigatran cost effective

2012 NHS Economic Evaluation Database.

65. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Full Text available with Trip Pro

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Kansal AR, Sharma M (...) , Bradley-Kennedy C, Clemens A, Monz BU, Peng S, Roskell N, Sorensen SV Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of dabigatran versus rivaroxaban as anticoagulation therapies for prevention

2012 NHS Economic Evaluation Database.

66. What role can dabigatran,rivaroxaban and apixaban play in the future?

What role can dabigatran,rivaroxaban and apixaban play in the future? Vol 19. DTB: Vol 19, No 3. May - July 2011 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DTB: Vol 19, No 3. May - July 2011 DTB: Vol 19, No 3. May - July 2011 Content tools Share it What role can dabigatran, rivaroxaban and apixaban play in the future? Dabigatran, rivaroxaban and apixaban have shown to be non inferior to warfarin. However these drugs might

2011 Drug and Therapeutics Bulletin of Navarre (Spain)

67. Acutely injured patients on dabigatran. (Abstract)

Acutely injured patients on dabigatran. 22111735 2011 12 09 2015 11 19 1533-4406 365 21 2011 Nov 24 The New England journal of medicine N. Engl. J. Med. Acutely injured patients on dabigatran. 2039-40 10.1056/NEJMc1111095 Cotton Bryan A BA McCarthy James J JJ Holcomb John B JB eng Letter United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Benzimidazoles 11P2JDE17B beta-Alanine I0VM4M70GC Dabigatran AIM IM N Engl J Med. 2012 Mar 1;366(9):863; author reply 864 22375993 Anticoagulants (...) adverse effects Benzimidazoles adverse effects Dabigatran Hemorrhage chemically induced Humans Thrombelastography Whole Blood Coagulation Time Wounds and Injuries complications beta-Alanine adverse effects analogs & derivatives 2011 11 25 6 0 2011 11 25 6 0 2011 12 14 6 0 ppublish 22111735 10.1056/NEJMc1111095

2011 NEJM

68. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Full Text available with Trip Pro

Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Shah SV, Gage BF Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of treatments to prevent stroke in patients with atrial fibrillation. The authors concluded that dabigatran 150mg twice daily was cost-effective for populations at high risk of haemorrhage or stroke, unless the control of the international normalised ratio with warfarin was excellent. The methods were good and reported adequately, with the results reported in full. Given the scope of the analysis

2011 NHS Economic Evaluation Database.

69. Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery

Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery (...) Ringerike T, Hamidi V, Hagen G, Reikvam A, Klemp M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ringerike T, Hamidi V, Hagen G, Reikvam A, Klemp M. Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery. Oslo: Norwegian Knowledge Centre

2011 Health Technology Assessment (HTA) Database.

70. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Full Text available with Trip Pro

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of low- or high-dose dabigatran, compared with warfarin, for the prevention of ischaemic stroke in patients aged 65 years or older, with non-valvular atrial fibrillation and risk factors for stroke. The authors concluded that dabigatran, particularly at a high

2011 NHS Economic Evaluation Database.

71. Dabigatran and rivaroxaban for prevention of venous thromboembolism: systematic review and adjusted indirect comparison

Dabigatran and rivaroxaban for prevention of venous thromboembolism: systematic review and adjusted indirect comparison Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

72. [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery]

[Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Dabigatran y rivaroxaban como tromboprofilaxis luego de una cirugia ortopedica mayor [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Dabigatran y rivaroxaban como tromboprofilaxis luego de una cirugia ortopedica mayor [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L (...) . Dabigatran y rivaroxaban como tromboprofilaxis luego de una cirugia ortopedica mayor. [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe Tecnico Breve No 41. 2011 Authors' objectives To assess the available evidence on the efficacy, safety and other issues related with coverage policies on the use of dabigatran and rivaroxaban as thrombophylaxis after a major orthopedic surgery. Authors

2011 Health Technology Assessment (HTA) Database.

73. Dabigatran etexilate - Prevention of stroke and systemic embolism in patients with atrial fibrillation

Dabigatran etexilate - Prevention of stroke and systemic embolism in patients with atrial fibrillation CEDAC M Notice of © 2011 C New I Recomm The Can listed for meeting • P n r e a o • P Reason 1. In on stroke daily with d comp dabig obse 2. The d when Backgro This sub Canada fibrillation through d indication Meeting – Mar CEDAC Fina ADTH Indication: mendation: adian Exper the prevent one of the fo Patients in w normalized r regular INR t education. P anticoagulati or Patients who for the Rec (...) e large open e or systemi (1.11%) com dabigatran 1 pared with ad gatran 150 m rved in centr daily cost of n monitoring ound: mission for d indication of n, in whom a direct inhibit n. The Healt rch 23, 2011; l Recommend CEDA [Pradax – : Preventio rt Drug Advis ion of stroke ollowing crite whom warfar ratio (INR) co testing, dosa Patients who ion managem o have a hist commendati n-label rando ic embolism mpared with 10 mg twice djusted dose mg twice dail res that faile dabigatran ( costs

2011 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

74. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. Full Text available with Trip Pro

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial.The RE-LY trial randomized 18 (...) 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median follow-up of 2.0 years. Compared with warfarin, dabigatran 110 mg twice a day was associated with a lower risk of major bleeding (2.87% versus 3.57%; P=0.002), whereas dabigatran 150 mg twice a day was associated with a similar risk of major bleeding (3.31% versus 3.57%; P=0.32). There was a significant treatment-by-age interaction

2011 EvidenceUpdates Controlled trial quality: uncertain

75. Dabigatran for atrial fibrillation: Why we can not rely on RE-LY

Dabigatran for atrial fibrillation: Why we can not rely on RE-LY January - March 2011 80 © Tel.: 604 822•0700 Fax: 604 822•0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 MI RE-LY-able? monitor SAE ? 3x intracranial hemorrhage? non-blinding bias Dabigatran for atrial fibrillation Why we can not rely on RE-LY (...) an estimate of net health benefit; the numerical difference (1.6%) favouring the lower dose bare- ly misses statistical significance. Based on its benefit for stroke, both the FDA and Health Canada approved only the 150 mg BID dose of dabigatran for patients with non-valvular atrial fibrillation 3 ; the European Medicines Agency approved both 150 and 110 mg BID 4 . Alternative interpretations of the data shown in Table 1 are that 110 mg BID provides a net health benefit over 150 mg BID

2011 Therapeutics Letter

76. Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran. Full Text available with Trip Pro

Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran. 21488759 2011 06 01 2015 11 19 1533-4406 364 19 2011 May 12 The New England journal of medicine N. Engl. J. Med. Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran. 1788-90 10.1056/NEJMp1103050 Beasley B Nhi BN Division of Cardiovascular and Renal Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA (...) . Unger Ellis F EF Temple Robert R eng Journal Article 2011 04 13 United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Benzimidazoles 11P2JDE17B beta-Alanine 5Q7ZVV76EI Warfarin I0VM4M70GC Dabigatran AIM IM Anticoagulants administration & dosage adverse effects Atrial Fibrillation drug therapy Benzimidazoles administration & dosage adverse effects Dabigatran Drug Approval Embolism prevention & control Hemorrhage chemically induced Humans Stroke prevention & control Therapeutic Equivalency

2011 NEJM

77. [Dabigatran etexilate for the prevention of stroke or systemic embolism in patients with non-vascular atrial fibrillation]

[Dabigatran etexilate for the prevention of stroke or systemic embolism in patients with non-vascular atrial fibrillation] Dabigatran etexilat en la profilaxi de l'accident vascular cerebral i de l'embolisme sistèmic en fibril·lació auricular no valvular [Dabigatran etexilate for the prevention of stroke or systemic embolism in patients with non-vascular atrial fibrillation] Dabigatran etexilat en la profilaxi de l'accident vascular cerebral i de l'embolisme sistèmic en fibril·lació auricular (...) no valvular [Dabigatran etexilate for the prevention of stroke or systemic embolism in patients with non-vascular atrial fibrillation] Gómez D, Paladio N, Almazán C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Gómez D, Paladio N, Almazán C. Dabigatran etexilat en la profilaxi de l'accident vascular cerebral i de l'embolisme sistèmic en

2011 Health Technology Assessment (HTA) Database.

78. [Dabigatran to prevent stroke in patients with atrial fibrillation]

[Dabigatran to prevent stroke in patients with atrial fibrillation] Dabigatran för att förebygga stroke vid förmaksflimmer [Dabigatran to prevent stroke in patients with atrial fibrillation] Dabigatran för att förebygga stroke vid förmaksflimmer [Dabigatran to prevent stroke in patients with atrial fibrillation] SBU Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation SBU. Dabigatran för att förebygga stroke vid förmaksflimmer. [Dabigatran to prevent stroke in patients with atrial fibrillation] Stockholm: The Swedish Council on Health Technology Assessment (SBU). SBU Alert 2011-04. 2011 Final publication URL Additional data URL Indexing Status Subject indexing assigned by CRD MeSH Atrial Fibrillations; Benzimidazoles; Pyridines; Stroke Language Published Swedish Country of organisation Sweden English summary An English language summary

2011 Health Technology Assessment (HTA) Database.

79. [Dabigatran for the prevention of ischemic stroke in patients with acute or chronic atrial fibrillation]

[Dabigatran for the prevention of ischemic stroke in patients with acute or chronic atrial fibrillation] Dabigatrán en la prevención del accidente cerebrovascular isquémico en pacientes con fibrilación auricular [Dabigatran for the prevention of ischemic stroke in patients with acute or chronic atrial fibrillation] Dabigatrán en la prevención del accidente cerebrovascular isquémico en pacientes con fibrilación auricular [Dabigatran for the prevention of ischemic stroke in patients with acute (...) cerebrovascular isquémico en pacientes con fibrilación auricular. [Dabigatran for the prevention of ischemic stroke in patients with acute or chronic atrial fibrillation] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N°249. 2011 Authors' objectives The purpose of this report is to assess the evidence available on the efficacy, safety and issues related to coverage policies on the use of dabigatran for the prevention of ischemic stroke (IS) in patients

2011 Health Technology Assessment (HTA) Database.

80. Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation. (Abstract)

Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation. Warfarin reduces the risk for ischemic stroke in patients with atrial fibrillation (AF) but increases the risk for hemorrhage. Dabigatran is a fixed-dose, oral direct thrombin inhibitor with similar or reduced rates of ischemic stroke and intracranial hemorrhage in patients with AF compared with those of warfarin.To estimate the quality-adjusted survival, costs, and cost-effectiveness (...) of dabigatran compared with adjusted-dose warfarin for preventing ischemic stroke in patients 65 years or older with nonvalvular AF.Markov decision model.The RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial and other published studies of anticoagulation. The cost of dabigatran was estimated on the basis of pricing in the United Kingdom.Patients aged 65 years or older with nonvalvular AF and risk factors for stroke (CHADS₂ score ≥1 or equivalent) and no contraindications

2010 Annals of Internal Medicine